The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
The dopamine D3 receptor, a quarter century later
Open accessAbstract
This review updates the existing knowledge suggesting a role for the D3 receptor in schizophrenia and drug addiction. The D3 receptor is expressed in brain regions controlling reward, emotions, and motivation. Antipsychotics bind in vitro to the D3 receptor with similar affinity as to the D2 receptor, and occupancy of D3 receptors in vivo by these compounds given acutely at clinical dosage have been demonstrated in Positron Emission Tomography (PET) studies. The D3 receptor modulates glutamatergic pathways from the prefrontal cortex to subcortical areas, either directly by interacting with N‐methyl‐D‐aspartate (NMDA) receptors in the nucleus accumbens, or indirectly by controlling dopamine release from ventral tegmental area neurons. In animals, D3 receptor antagonists reverse behavioral manifestations of NMDA receptor blockade and improve cognitive performances in various paradigms. Two D3 receptor‐selective compounds have reached clinical trials in schizophrenia, with negative results seemingly due to insufficient target engagement; the results with a third compound, F17464, have not been disclosed yet. There is converging evidence that D3 receptors do not control the reinforcing effects of drugs of abuse (with the exception of alcohol under low requirement), but rather affects the motivation to take the drugs under high requirement, reactivity to drug‐associated cues, and drug‐seeking behaviors triggered by stimuli associated with relapse in humans. D3 receptor expression measured by PET is upregulated in humans with various drug addictions. A single administration of the D3 receptor‐selective antagonist,GSK 598809, in humans transiently alleviated craving in smokers after overnight abstinence. The clinical development of D3‐selective compounds will benefit from initial assessment of target engagement through the use of PET.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
The reinstatement model of drug relapse: history, methodology and major findings
Shaham, Y., Shalev, U., Lu, L., de Wit, H., & Stewart, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1224-x · Cited by 1,615
The principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Reinstatement of cocaine-reinforced responding in the rat
de Wit, H., & Stewart, J. (1981) · Psychopharmacology · doi:10.1007/bf00432175 · Cited by 928
Characteristics of Excitatory and Inhibitory Synapses in the Central Nervous System of the Cat
UCHIZONO, K. (1965) · Nature · doi:10.1038/207642a0 · Cited by 917 · cited 2×
“Synapses of the asymmetric type are typical of glutamatergic synapses (Uchizono, 1965; Kemp & Powell, 1971), whereas the majority of presumed dopamine terminals forms symmetric synapses (Arluison et al., 1984; Bolam et al., 2000), where D3 receptorassociated immunoreactivity was rarely observed.”
BackgroundVolkow, N. D., Chang, L., Wang, G.-J., Fowler, J. S., Ding, Y.-S., Sedler, M., Logan, J., Franceschi, D., Gatley, J., Hitzemann, R., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2015 · Cited by 916
Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration
Morgan, D., Grant, K. A., Gage, H. D., Mach, R. H., Kaplan, J. R., Prioleau, O., Nader, S. H., Buchheimer, N., Ehrenkaufer, R. L., & Nader, M. A. (2002) · Nature Neuroscience · doi:10.1038/nn798 · Cited by 674
Cited by
Correll, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update
Voon, V., Napier, T. C., Frank, M. J., Sgambato-Faure, V., Grace, A. A., Rodriguez-Oroz, M., Obeso, J., Bezard, E., & Fernagut, P.-O. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30004-2 · Cited by 359
Le Foll, B., Piper, M. E., Fowler, C. D., Tonstad, S., Bierut, L., Lu, L., Jha, P., & Hall, W. D. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00346-w · Cited by 316
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Dopaminergic basis for signaling belief updates, but not surprise, and the link to paranoia
Nour, M. M., Dahoun, T., Schwartenbeck, P., Adams, R. A., FitzGerald, T. H. B., Coello, C., Wall, M. B., Dolan, R. J., & Howes, O. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809298115 · Cited by 101
Papp, M., Gruca, P., Lason-Tyburkiewicz, M., Litwa, E., Niemczyk, M., Tota-Glowczyk, K., & Willner, P. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4651-4 · Cited by 40
Jordan, C. J., & Xi, Z.-X. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.811192 · Cited by 20
Metadata
- Authors
- Sokoloff, P., & Le Foll, B.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2016-10-03
- Volume
- 45
- Issue
- 1
- Pages
- 2-19
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W2509180953
- Cited by
- 224
- References
- 17
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.